Pre-treatment of the beta3-adrenergic receptor agonist BRL37344 reduces in vivo myocardial ischemia/reperfusion injury by improving AMPK and SIRT1 activity and by suppressing mTOR and p70S6K signaling pathways. Braz. J. Pharm. Sci. [Internet]. 2023 Nov. 3 [cited 2024 Dec. 26];59:e23002. Available from: https://revistas.usp.br/bjps/article/view/226640